Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John P Maxwell

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
The Journal of Organic Chemistry|April 12, 2003
Mild, fast, and stereoselective epoxide opening by ketone enolate anions. Application to synthesis of the norlignan curculigineGary H Posner, John P Maxwell, Mehmet Kahraman
Current Opinion in Supportive and Palliative Care|November 6, 2019
Dealing with prognostic uncertainty: the role of prognostic models and websites for patients with advanced cancerDavid Hui, John P Maxwell, Carlos Eduardo Paiva
Diseases of the Colon and Rectum|December 8, 2016
Immunonutrition and Colorectal SurgeryStephen A McClave, Robert G Martindale, John P Maxwell
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 25, 2025
When would I be surprised? Variability in predicted probability of survival for being "surprised" and "not surprised" to the surprise questionDavid Hui, Amy Ontai, Clark Andersen, et al.
Journal of Medicinal Chemistry|May 18, 2026
The Discovery of TNG456: A Highly Potent, Selective, Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor for the Treatment of <i>MTAP</i>-Deleted CancersKevin M Cottrell, Kimberly J Briggs, Alice Tsai, et al.
Journal of Medicinal Chemistry|February 7, 2025
MTA-Cooperative PRMT5 Inhibitors: Mechanism Switching Through Structure-Based DesignKevin M Cottrell, Douglas A Whittington, Kimberly J Briggs, et al.
Journal of Medicinal Chemistry|March 4, 2025
Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with <i>MTAP</i> DeletionKevin M Cottrell, Kimberly J Briggs, Alice Tsai, et al.
Bioorganic & Medicinal Chemistry Letters|May 8, 2007
Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokineticsRobert B Perni, Gurudatt Chandorkar, Kevin M Cottrell, et al.
Translational Oncology|January 5, 2025
TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancersKimberly J Briggs, Kevin M Cottrell, Matthew R Tonini, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 8, 2024
The impact of a web-based prognostic calculator on prognostic confidence in outpatient palliative careDavid Hui, John P Maxwell, Allison de la Rosa, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
The Journal of Organic Chemistry|April 12, 2003
Mild, fast, and stereoselective epoxide opening by ketone enolate anions. Application to synthesis of the norlignan curculigineGary H Posner, John P Maxwell, Mehmet Kahraman
Current Opinion in Supportive and Palliative Care|November 6, 2019
Dealing with prognostic uncertainty: the role of prognostic models and websites for patients with advanced cancerDavid Hui, John P Maxwell, Carlos Eduardo Paiva
Diseases of the Colon and Rectum|December 8, 2016
Immunonutrition and Colorectal SurgeryStephen A McClave, Robert G Martindale, John P Maxwell
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 25, 2025
When would I be surprised? Variability in predicted probability of survival for being "surprised" and "not surprised" to the surprise questionDavid Hui, Amy Ontai, Clark Andersen, et al.
Journal of Medicinal Chemistry|May 18, 2026
The Discovery of TNG456: A Highly Potent, Selective, Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor for the Treatment of <i>MTAP</i>-Deleted CancersKevin M Cottrell, Kimberly J Briggs, Alice Tsai, et al.
Journal of Medicinal Chemistry|February 7, 2025
MTA-Cooperative PRMT5 Inhibitors: Mechanism Switching Through Structure-Based DesignKevin M Cottrell, Douglas A Whittington, Kimberly J Briggs, et al.
Journal of Medicinal Chemistry|March 4, 2025
Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with <i>MTAP</i> DeletionKevin M Cottrell, Kimberly J Briggs, Alice Tsai, et al.
Bioorganic & Medicinal Chemistry Letters|May 8, 2007
Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokineticsRobert B Perni, Gurudatt Chandorkar, Kevin M Cottrell, et al.
Translational Oncology|January 5, 2025
TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancersKimberly J Briggs, Kevin M Cottrell, Matthew R Tonini, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 8, 2024
The impact of a web-based prognostic calculator on prognostic confidence in outpatient palliative careDavid Hui, John P Maxwell, Allison de la Rosa, et al.
Pageof 3